Insider Trends: Insider Prolongs Selling Trend at Spero Therapeutics
06:48 PM EST, 02/04/2021 (MT Newswires) -- Aquilo Capital Management Llc, 10% Owner, on Feb 01, 2021, sold 100,000 shares in Spero Therapeutics (SPRO) for $1,901,987. Subsequent to the Form 4 filing with the SEC, Aquilo Capital Management has indirect ownership of 3,832,209 shares of the company, which has a market value of $72.7 million as of the prior-day closing price.
Over the last 90 days, prior to the date of this filing, there have been 4 insider transactions reported to the SEC for Spero Therapeutics. These transactions came from the activities of 2 separate insiders that resulted in a net disposition of 390,833 company shares. Relative to the preceding 90-day window of time, there were 9 transactions from 2 insiders that resulted in the net disposition of 174,100 shares.
This is below the average for insider transactions in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Activity in the peer group averaged 56.2 transactions per company, with company insiders acquiring on average 24,484 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1701108/000159198621000001/xslF345X03/primary_doc.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.